# Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Heterologous Protection Induced by Immunization With Invaplex Vaccine
**AGENCY:**
Department of the Army, DoD.
**ACTION:**
Notice.
**SUMMARY:**
In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 10/150,814 entitled “Heterologous Protection Induced by Immunization with Invaplex Vaccine,” filed May 17, 2002. Foreign rights (PCT/US02/16029) are also available. The United States Government, as represented by the Secretary of the Army has rights in this invention.
**ADDRESSES:**
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.
**FOR FURTHER INFORMATION CONTACT:**
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.
**SUPPLEMENTARY INFORMATION:**
In this application is described a composition, Invaplex, derived from a gram negative bacteria for use in generating an immune response in a subject against one or more heterologous species or strains of gram-negative bacteria.
Luz D. Ortiz,
Army Federal Register Liaison Officer.